Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy

1. Urruticoechea, A.
2. Rizwanullah, M.
3. Im, S.-A.
4. Sánchez Ruiz, A.C.
5. Láng, I.
6. Tomasello, G.
7. Douthwaite, H.
8. Crnjevic, T.B.
9. Heeson, S.
10. Eng-Wong, J.
11. Muñoz, M.